Xilio Therapeutics, Inc. Proceeds from Long-Term Debt Issued
Xilio Therapeutics, Inc. (XLO) reported Proceeds from Long-Term Debt Issued of $975.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-02.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2023-03-02
- Xilio Therapeutics, Inc. proceeds from issuance of long-term debt for the quarter ending 2021-12-31 was $0.00.
- Xilio Therapeutics, Inc. proceeds from issuance of long-term debt for fiscal 2021 was $975.00K.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $975.00K 10-K · filed 2023-03-02 | |
| 2021-09-30 | $975.00K 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |